A detailed history of Bellevue Group Ag transactions in Verona Pharma PLC stock. As of the latest transaction made, Bellevue Group Ag holds 1,139,295 shares of VRNA stock, worth $17.6 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares
1,139,295
Previous 839,996 35.63%
Holding current value
$17.6 Million
Previous $16.7 Million 9.77%
% of portfolio
0.29%
Previous 0.26%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$15.3 - $20.24 $4.58 Million - $6.06 Million
299,299 Added 35.63%
1,139,295 $18.3 Million
Q4 2023

Feb 14, 2024

SELL
$11.94 - $20.47 $195,362 - $334,930
-16,362 Reduced 1.91%
839,996 $16.7 Million
Q3 2023

Nov 14, 2023

BUY
$16.3 - $22.09 $4.63 Million - $6.27 Million
284,043 Added 49.63%
856,358 $14 Million
Q2 2023

Aug 14, 2023

BUY
$19.41 - $23.43 $6.01 Million - $7.25 Million
309,632 Added 117.87%
572,315 $12.1 Million
Q1 2023

May 15, 2023

BUY
$18.06 - $25.27 $4.74 Million - $6.64 Million
262,683 New
262,683 $5.27 Million

Others Institutions Holding VRNA

About Verona Pharma plc


  • Ticker VRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,954,200
  • Market Cap $942M
  • Description
  • Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...
More about VRNA
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.